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Objectives: Using synchronous cultures of Plasmodium falciparum malaria, the stage sensitivity of the
parasite to OZ277 (RBx-11160), the first fully synthetic antimalarial peroxide that has entered Phase II
clinical trials, was investigated in vitro over a concentration range of 1· to 100· the IC50. Secondly,
partitioning of OZ277 into P. falciparum-infected red blood cells (RBCs) and uninfected RBCswas studied
in vitro by measuring its distribution between RBCs and plasma (R/P).
Methods:Theeffectsof timed invitroexposure (1, 6, 12or24h) toOZ277weremonitoredby incorporationof
[3H]hypoxanthine into parasite nucleic acids and by light-microscopic analysis of parasite morphology.
Partitioning studies were performed with radiolabelled [14C]OZ277.
Results: After 1 h of exposure to OZ277 at the highest concentration (100· the IC50) followed by removal of
the compound, the hypoxanthine assay showed that growthofmature stages ofP. falciparumwas reduced
to below 20%. Young ring forms were slightly less sensitive (43% growth). Similar stage-specific profiles
were found for the antimalarial reference compounds artemether and chloroquine. Strong inhibition (£6%
growth) of all parasite stages was observed when the parasites were exposed to each of the three com-
pounds for 6 h or longer. After removal of the compounds, the parasites did not recover, indicating that the
observed growth inhibitions were cytotoxic rather than cytostatic. Pyrimethamine was confirmed to be
active exclusively against young schizonts. Light-microscopic analysis also demonstrated the specificity
of pyrimethamine against the schizont forms and showed that OZ277, artemether and chloroquine attenu-
ated parasite growthmore rapidly than did pyrimethamine. The R/P for OZ277 was 1.5 for uninfected RBCs
and up to 270 for infected RBCs.
Conclusions: The present study indicates similar stage-specific profiles for OZ277 and for the more well-
established antimalarial agents artemether and chloroquine. Secondly, the study describes a significant
accumulation of radiolabelled OZ277 in P. falciparum-infected RBCs.
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Introduction
The sesquiterpene lactone artemisinin was isolated by Chinese
scientists in 1971 by extraction of Artemisia annua (the sweet
wormwood plant) into diethyl ether at low temperature. The
‘active principle’ was subsequently shown to cure mice infected
with Plasmodium berghei. In 1972, further work culminated
in the isolation of a crystalline compound that was named
qinghaosu, or artemisinin, after the generic name of the plant1
and demonstrated that its peroxide bond is essential for antimal-
arial activity.2,3 Artemisinin can be converted into its semisyn-
thetic derivatives, artemether and artesunate, which are more
active than the parent molecule.4 However, the isolation of arte-
misinin from the plant makes it and its semisynthetic derivatives
several fold more expensive than the relatively inexpensive stand-
ard antimalarials chloroquine and pyrimethamine/sulfadoxine.
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The first total synthesis (13 steps, 5% overall yield) of artemi-
sinin was reported in 1983.5 Since then, several groups have
reported different pathways for the synthesis of artemisinin,
but all require numerous steps and have low yields.6–8 Thus,
none of these complex syntheses provides a viable method
for large-scale production of the molecule.9 Although the
semisynthetic artemisinins (in combination with longer acting
antimalarials) are currently the drugs of choice to treat
multidrug-resistant malaria, access to these agents in disease
endemic countries has been limited mainly due to their cost
and availability. Recently, Vennerstrom et al.10 published the
discovery of a new synthetic peroxide antimalarial called
OZ277 (RBx-11160). OZ277, currently in Phase II clinical trials,
exhibits structural simplicity, an economically feasible and
scalable synthesis, superior antimalarial activity and a better
biopharmaceutical profile than artemisinin and its semisynthetic
derivatives. Furthermore, OZ277 is fully synthetic and structur-
ally different from the artemisinin drug class. Artemisinins con-
tain a six-membered 1,2,4-trioxane heterocycle whereas OZ277
contains a five-membered 1,2,4-trioxolane, more commonly
known as a secondary ozonide. The present study describes
for the first time the pharmacodynamic effects of this novel
drug development candidate on Plasmodium falciparum cultures
by assessing its stage specificity and rate of action in comparison
with three standard antimalarial drugs at clinically relevant
concentrations. The partitioning of OZ277 into infected and
non-infected red blood cells (RBCs) was also examined.
Materials and methods
Chemicals and materials
Chemicals and materials were from Sigma, Perkin-Elmer and
GIBCO Invitrogen except for OZ277 tosylate (J. L. Vennerstrom,
Nebraska, USA), artemether (Kunming Pharmaceuticals Corporation,
China), pyrimethamine (Roche, Basel, Switzerland) and [8-3H]hypox-
anthine (Amersham Bioscience, UK). Antimalarial compounds were
dissolved in dimethylsulfoxide (DMSO) at 10 mg/mL. The stock
solutions were kept at 4C for not more than 6 months. Two
[14C]OZ277 hydrogen maleate salts (508 g/mol) were used—one
was labelled in the adamantane ring (OZ277[L], Moravek Biochem-
icals; specific activity: 31 mCi/mmol) and the other in the side chain
(OZ277[R], a gift from F. Hoffmann-La Roche Ltd; specific activity:
42 mCi/mmol, Figure 1). The compounds were prepared as 10 mg/mL
stock solutions in toluene and stored at –80C.
Parasite cultivation
NF54, a drug-sensitive isolate of P. falciparum, was maintained in
10 cm Petri dishes and cultured by standard methods11 in an atmo-
sphere of 93% N2, 4% CO2, 3% O2 at 37
C. The culture medium was
RPMI 1640 10.44 g/L, supplemented with Hepes 5.94 g/L, Albumax
II 5 g/L, hypoxanthine 50 mg/L, sodium bicarbonate 2.1 g/L and
neomycin 100 mg/L. When required, parasites were synchronized
twice with 5% D-sorbitol.12 The second treatment was 7–8 h after the
first. This procedure provided in most cases a parasite culture con-
taining ‡80% young trophozoites (20 h old). Initial parasitaemias
varied between 3% and 11% in all studies.
Growth inhibition assay and washing procedure
P. falciparum growth was assessed by measuring incorporation of the
nucleic acid precursor [3H]hypoxanthine.13 IC50 values were found to
be 0.91 – 0.12 ng/mL for OZ277, 1.2 – 0.1 ng/mL for artemether,
5.1 – 0.8 ng/mL for chloroquine10 and 5.6 – 0.5 ng/mL for pyri-
methamine. Synchronized cultures of young NF54 trophozoites (20 h)
with parasite counts of 0.15% and a haematocrit of 5% were divided
into three 10 cm Petri dishes. Two dishes were further incubated for
16 or 32 h at 37C for maturation into early schizonts (36 h) or early
ring stages (4 h). The third dish with the early trophozoites was used
immediately for exposure for a 1, 6, 12 or 24 h period to the fol-
lowing four antimalarial compounds: OZ277 and artemether (final
concentrations 100, 13, 1.6 ng/mL), chloroquine and pyrimethamine
(final concentrations 500, 63, 8 ng/mL). After the respective incuba-
tion times for the parasite–compound mixture, the plates were
washed four times resulting in a 1280-fold dilution of the free com-
pound. After another incubation period of 24 h at 37C in the atmo-
sphere described above and in the presence of [3H]hypoxanthine, the
plates were frozen at –20C. For the IC50 determination, plates were
thawed and harvested with a Betaplate cell harvester (1295-004
Betaplate; Wallac Perkin-Elmer) onto glass filters. The dried filters
were inserted into a plastic foil with 10 mL of scintillation fluid and
counted in a Betaplate liquid scintillation counter (1205 Betaplate;
Wallac Perkin-Elmer). The results of each well were recorded as
counts per min and expressed as a percentage of the untreated con-
trols. Suspensions of uninfected erythrocytes were used for back-
ground subtraction. For morphological analysis of antimalarial
action, synchronized cultures were treated with compounds (100·
IC50) in 10 cm Petri dishes. Light-microscopic evaluation of Giemsa-
stained thin blood smears was performed every hour by using an
oil-immersion lens (1000·). Changes in parasite morphology were
compared with compound-free control cultures.
Time-course of uptake into RBCs
Samples containing 230 mL of infected erythrocytes and 470 mL of
plasma at a final OZ277 concentration of 77 ng/mL (as either the R
or L radiolabelled material, Figure 1) were incubated in a water bath
at 37C for various time periods ranging from 10 min up to 3 h. At
the end of the incubation period, tubes were centrifuged at 600 g for
5 min to form RBC pellets; 230 mL of each supernatant was trans-
ferred to a new tube. The rest of the supernatant was discarded and
the pellets (230 mL) were kept for further processing. In addition, all
experiments included the following two controls: (i) 700 mL of
plasma (no RBCs) containing a final [14C]OZ277 concentration
of 77 ng/mL was incubated for 20 min and 2 h; and (ii) a mixture
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Figure 1. Structure of the two [14C]OZ277 molecules. One was labelled in the
adamantane ring (OZ277[L], Moravek Biochemicals) and the other in the side
chain (OZ277[R], a gift from F. Hoffmann-LaRoche Ltd). The asterisk denotes
the position of the 14C label.
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of 470 mL of plasma (containing no [14C]OZ277) and 230 mL of
uninfected RBCs was incubated for 1 h. From tube (i) 230 mL of the
drug mixture and from the background-control (ii) 230 mL of
the supernatant were also transferred to new tubes. Then, to each
of the tubes containing the various controls, test supernatants and
pellets, 1 mL of a 50:50 mixture of isopropanol and soluene-350 was
added, followed by incubation at 60C for 1 h in a water bath. The
samples were then bleached with 3.2 mL of 30% hydrogen peroxide
and again incubated at 60C for 30 min in a water bath. Finally,
15 mL of OptiPhase ‘Super Mix’ scintillation cocktail was added.
The contents of the tubes were mixed, 4 mL transferred to scintil-
lation vials and counted after 3–4 h using a liquid scintillation coun-
ter (1450 Microbeta plus; Wallac Perkin-Elmer). To confirm mass
balance and the absence of a significant contribution of extracellular
fluid on the measured counts for the pellet, the counts for the total
test-vial sample volume were calculated from the measured counts
for the plasma supernatant and the RBC pellet. This value was then
compared with the total counts for the plasma control (i). Results
were not considered if the measured counts of OZ277 for the plasma
control (i) differed by more than 10% from that calculated for the
test-vial (containing RBCs and plasma). For the vast majority of the
experiments, total counts for the control and test vials differed by
<10%. Results of the background-control (ii) were used for back-
ground subtraction. Where uptake ratios (R/P; i.e. gradient between
RBCs and plasma) were calculated, they represented the calculated
ratio of radioactivity in 230 mL of 100% infected RBCs to the same
volume of plasma collected at the end of incubation. The uptake into
non-infected RBCs was accounted for by using the following
equation:
dpmI ¼
dpmR – dpmNð1– x100Þ
x
*100
where dpmI = dpm in 230 mL of 100% infected erythrocytes, dpmR =
dpm in 230 mL of infected cell pellet (i.e. containing infected
and non-infected RBCs), dpmN = dpm in 230 mL of non-infected
cell pellet (i.e. containing only non-infected RBCs) and x = %
parasitaemia.
R/P was then calculated by dividing dpmI by dpm in 230 mL of
plasma collected at the end of incubation.
Effect of compound concentration on RBC uptake
Infected or uninfected erythrocytes (230 mL) were mixed with
420 mL of plasma and 50 mL of [14C]OZ277[L] in plasma at con-
centrations ranging from 40 to 64 000 ng/mL. All samples, including
controls (i) and (ii), were incubated for 1 h at 37C. Extraction of
the samples was performed as described above.
Results
Pharmacodynamic studies
Stage-specific effects of 1, 6, 12 or 24 h of compound exposure
were investigated using the hypoxanthine incorporation assay
with highly synchronous cultures of P. falciparum NF54 over
a concentration range of 1· to 100· the IC50 of the four com-
pounds OZ277, artemether, chloroquine and pyrimethamine. The
washing procedure following the respective incubation periods
was performed in a way that the unbound compound was diluted
at least 1000-fold. Using this procedure, the viability of parasites
during the subsequent [3H]hypoxanthine-incubation period of
24 h could be assessed in the absence of unbound compound.
Parasitic stages evaluated were young rings (4 h), young
trophozoites (20 h) and young schizonts (36 h). Figure 2
shows parasite growth plotted against incubation time for three
selected compound concentrations: 1· IC50, 10· IC50 and
100· IC50. After 1 h of exposure to OZ277, artemether or
chloroquine at the highest concentration (100· the IC50), ring
forms were slightly more resistant to the three compounds
than trophozoites and schizonts. From 6 up to 24 h of compound
incubation, all stages reacted similarly, with strong inhibition
(£6% growth) at 100· IC50. Interestingly, at the lowest OZ277
concentration (1· IC50), schizonts underwent a steady decrease
of growth after 6 h, then an increase at 12 h and a decrease at
24 h. The marked increase in growth after 12 h was repeated and
confirmed in three independent experiments. The growth inhibi-
tion of ring and trophozoite populations remained relatively
stable from 6 h onwards. At the lowest artemether concentration
tested (1· IC50), a minimal inhibitory effect was observed
against all parasite forms over the entire period investigated,
whereas at the lowest chloroquine concentration a relatively
linear decrease of growth within 24 h was noted for all stages.
Stage-specific analysis with pyrimethamine demonstrated that
growth of the ring and trophozoite stages was not affected,
even after 24 h at the highest concentration. The only pyri-
methamine-sensitive parasite form was the schizont. Growth
inhibition of 20–40% was observed after 6 and 12 h at medium
to high pyrimethamine concentrations. The 24 h incubation per-
iod clearly resulted in the strongest schizont growth inhibition,
even at the lowest concentration. To determine the morphological
changes of P. falciparum by light microscopy, synchronous cul-
tures of NF54 were exposed to OZ277, artemether, chloroquine
and pyrimethamine, respectively, at fixed compound concentra-
tions of 100· IC50. Thin, Giemsa-stained blood smears were
taken hourly from 1 to 9 h and after 24 h. The morphological
changes observed were very similar for OZ277, artemether and
chloroquine. In young ring forms, the nucleus was most affected
in the first 1–2 h. In schizont and trophozoite forms, the first
changes were observed usually after 1 and 3 h, respectively.
Morphology changes were clumping of crystals, a paler disor-
ganized cytoplasm and vacuolation (data not shown). In contrast
to OZ277, artemether and chloroquine, most of the pyrimetham-
ine-treated ring and trophozoite stages developed further to their
next stage, even up to the end of the monitoring period (24 h).
Only the cytoplasm of schizonts became paler and crystals started
to clump (8–9 h) until the parasites actually stopped developing
or disintegrated (24 h).
Time-course of uptake into RBCs
Table 1 shows the accumulation of [14C]OZ277[L] by uninfected
erythrocytes or erythrocytes infected with young and mature
parasites over a time period of 10 min up to 3 h at a compound
concentration of 77 ng/mL. Mature parasites accumulated the
compound more quickly and at a higher average ratio
(30 min, R/P = 214) than ring forms (2 h, R/P = 53). Based
on the R/P ratio at 3 h, concentrations of the radiolabelled com-
pound in infected RBCs of both mature and young parasite stages
declined to about half the maximum value. Under these same
conditions, uninfected erythrocytes showed an uptake ratio of
about 1.5, which was maintained throughout the 3 h incubation
period. Figure 3 shows the time-course of the two different
radiolabelled OZ277 molecules [L] and [R]. Young ring stages
tested at 10 min showed comparable uptake of both radiolabelled
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compounds. However after 10 min, the concentration of the [R]
molecules in the infected RBCs decreased steadily compared with
the [L] molecules. Uninfected RBCs incubated with OZ277[R]
showed similar uptake ratios compared with OZ277[L].
Effect of different compound concentrations on RBC uptake
The results from incubations conducted at concentrations of
38–64 000 ng/mL of radiolabelled OZ277[L] and analysed at a
single time-point of 1 h showed that at higher concentrations the
uptake ratios reached a constant value of 23 (Figure 4). Unin-
fected RBCs had a steady uptake ratio of about 2 (data not
shown) over this same incubation period.
Discussion
Relatively little is known about the rate of action and selective
toxicity of antimalarials against the morphologically distinguish-
able different blood stages of P. falciparum.14 These pharmaco-
dynamic factors may be important determinants of immediate
antimalarial drug efficacy in severe malaria and could provide
important clues about the mechanism of action. Another reason
for the selective toxicity of antimalarials such as chloroquine and
the artemisinin family of drugs can be attributed to the increased
accumulation in parasitized RBCs.15–18 Given these considera-
tions, we assessed in vitro the pharmacodynamic properties and
the partitioning of OZ277, the first fully synthetic antimalarial
peroxide that has entered Phase II clinical trials, in cultures of
P. falciparum.
Pharmacodynamic studies indicated that OZ277, artemether
and chloroquine influence growth of all parasite stages in a
similar way (Figure 2). An exposure time of ‡1 h at a high
compound concentration range was sufficient to achieve substan-
tial growth inhibition and morphological changes of all parasite
stages. However, at a relatively low compound concentration of
1· IC50, parasite growth was reduced only marginally, and after
24 h, chloroquine showed the strongest growth reduction effect
followed by OZ277 and artemether. These observations are con-
sistent with microscopic studies performed by Alin et al.19 and
Ye et al.20, who reported that an artemisinin concentration of
4 ng/mL for 48 h had no appreciable effect on the parasites. In
related studies, Ter Kuile et al.21 measured the antimalarial
effects of artemisinin, artelinic acid and other compounds by
inhibition of incorporation of [3H]hypoxanthine as an indicator
of nucleic acid synthesis, [3H]isoleucine as an indicator of protein
synthesis and lactate production as an indicator of parasite gly-
colysis. These authors stated that the trophozoite and schizont
stages were considerably more sensitive to artemisinin and
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Figure 2. Stage-dependent effects of OZ277, artemether, chloroquine and pyrimethamine (1·,10· and100· the IC50) on [3H]hypoxanthine incorporation in
synchronous cultures ofP. falciparum strainNF54. Compoundswere added for 1, 6, 12 or 24 h. After removal of the compounds, parasiteswere incubated for another
24 h in the presence of [3H]hypoxanthine. Compound effects are expressed as the percentage of growth of the respective development stage relative to untreated
control.White bars, ring stage; blackbars, trophozoite stage; hatchedbars, schizont stage.Each bar represents themeanofn=2 independent experiments.Variationof
individual valueswas low except forOZ277 ring stage at 1 h ( –65%at 13 ng/mLand –46%at 1.6 ng/mL) and pyrimethamine ring stage at 1 h (–31%at 63 ng/mL and
–55% at 8 ng/mL). Pyrimethamine 6 h experiment was only conducted once.
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artelinic acid than were the young ring stages. They also reported
that the inhibition was dose-dependent. Our results with arte-
mether at the 1 h time-point (1· up to 100· IC50) (Figure 2)
are in good agreement with these reports. Studies performed by
Geary et al.22 using the [3H]hypoxanthine assay also showed a
similar stage specificity for artemisinin. This is encouraging,
especially since a direct comparison of our results with those
of Ter Kuile et al.21 is difficult, because of the different meth-
odologies used in the two studies. Ter Kuile et al.21 used a higher
parasitaemia of 0.4–0.8% and a two cycle as well as a same cycle
experiment, factors that could have altered parasite growth, and
thereby efficacy profiles. Our data are also consistent with data
reported by Skinner et al.23 and Alin et al.19 Skinner et al.
showed that an IC90 concentration of dihydroartemisinin
(DHA) is rapidly effective against all three stages of the parasite.
In these experiments, a [3H]hypoxanthine assay was used to show
that young trophozoites (20–24 h) and young schizonts (36 h)
achieve 95% growth inhibition after 2 h of incubation. They
also observed ring forms to be more resistant, achieving 95%
growth inhibition only after 6 h. Surprisingly, in this same work,
the group demonstrated that artemether and artemisinin, unlike
DHA, showed relatively little activity against trophozoites, while
a more DHA-like effect was found against the other two forms.
The authors explained the discrepancy of their trophozoite result
with the relatively low compound concentration (IC90) used in
their experiments. Alin et al.19 performed microscopic counting
experiments with unsynchronized parasites that had been incub-
ated for 1 h with an artemisinin concentration range of 40–4000
ng/mL. They reported that 48 h after removal of the compound,
the predominant parasite stage that remained viable in culture
was rings. In contrast, after ‡6 h in the presence of compound, the
remaining viable stages were evenly distributed, suggesting that
£6 h is enough to affect all stages to the same extent.
In terms of chloroquine, our stage dependency data were in
good agreement with two studies using similar techniques.21,24
Both groups reported that trophozoite and schizont stages were
considerably more sensitive to the compound. Pyrimethamine is
the only compound that was found to be strongly stage specific
for young schizonts (Figure 2). However, this observation was
Table 1 Selective accumulation of [14C]OZ277[L] by uninfected RBCs and by RBCs infected with Plasmodium falciparum strain NF54
Total
parasitaemia (%)
Ring
(%)
Troph
(%)
Schizont
(%)
R/P
10 min
R/P
20 min
R/P
30 min
R/P
1 h
R/P
2 h
R/P
3 h
Uninfected RBCs Exp. 1 1.1 1.0 1.5 2.1 1.3 1.8
Uninfected RBCs Exp. 2 1.6 1.5 1.6 2.2 1.6 1.2
Mean of all 12 time points 1.5
Infected RBCs Exp. 1 3.8 0.1 0.5 3.2 80 124 270 165 91 95
Infected RBCs Exp. 2 4.8 0.2 1.4 3.2 87 162 157 173 108 77
Mean of each time point 84 143 214 169 100 86
Infected RBCs Exp. 3 8.3 6.8 1.5 – 19 22 44 47 64 17
Infected RBCs Exp. 4 11.3 10.8 0.5 – 19 21 31 39 41 32
Mean of each time point 19 22 38 43 53 25
The initial concentration of the drug was 77 ng/mL. R/P is the uptake ratio obtained from the disintegrations per minute (dpm) in 230 mL of pure parasitized RBCs
(correction made for 100% parasitaemia) divided by the dpm in 230 mL of plasma from the same tube.
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Figure 3. Time-course of uptake of [14C]OZ277[L] (black bars) and
[14C]OZ277[R] (white bars) from 10 min to 3 h by P. falciparum strain NF54
(ring stage). TheOZ277 concentrationwas 77ng/mL.One representative experi-
ment is shown for each compound. The horizontal line indicates the drug accu-
mulation in uninfected RBCs (R/P = 1.5).
0
20
40
60
80
100
120
0 1000 2000 3000
R
/P
60 000 80 000
Drug concentration (ng/mL)
Figure 4. Effect of initial external concentration of [14C]OZ277[L] on the dis-
tribution between RBCs infected with P. falciparum strain NF54 and plasma
(R/P). Data points represent the mean of n = 3 experiments (–SE) or the mean of
n = 2with individual values differing by <10%. Each experiment was performed
with unsynchronized parasite cultures incubated for 1 h in the presence of
radiolabelled compound.
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not unexpected, since similar data have been published pre-
viously by Dieckmann and Jung.25 These authors showed that
ring and trophozoite stages exposed to 10 nM (= 2.5 ng/mL)
pyrimethamine for 6 h grew normally after removal of the com-
pound, which is consistent with our observations for these para-
site stages. Of particular interest is that ring forms and
trophozoites were resistant to the compound up to the extreme
conditions tested (24 h at 500 ng/mL or 100· IC50). Young
schizonts, which had been exposed to 100· IC50 concentrations
of pyrimethamine for 12 h, still grew to about 60%. However, a
24 h incubation period resulted in quite strong growth inhibition,
even at relatively low pyrimethamine concentrations. Therefore, a
long pyrimethamine exposure time seems to be more critical for
schizont growth than a high compound concentration. This, and
the pronounced stage specificity for schizonts, distinguishes pyri-
methamine from the faster acting compounds OZ277, artemether
and chloroquine.
A feature of the specific activity of artemether and chloro-
quine is assumed to be their enrichment in malaria-infected
RBCs. Vyas et al.18 as well as Gu et al.16 found that [14C]arte-
misinin and [3H]DHA partition into P. falciparum-infected RBCs
and are accumulated up to 300-fold. This degree of concentration
also resembles that of chloroquine.15,17 We have obtained similar
results with [14C]OZ277 (Table 1), which suggest that the accu-
mulation of OZ277 by malaria-infected RBCs could be an
important aspect of the selective toxicity of this compound. Pre-
liminary studies have also suggested similar high accumulation of
OZ277 in P. berghei-infected erythrocytes (S. A. Charman,
unpublished data).
Time-course experiments performed with OZ277 radiolabelled
either in the adamantane ring (OZ277[L]) or in the right side
chain (OZ277[R]) showed that after 10 min, young ring forms
take up comparable amounts of both molecules (Figure 3). How-
ever, after 10 min the concentration of the [R] molecules in the
infected RBCs decreased steadily, whereas the [L] molecules
accumulated continuously, reaching their maximum after 2 h.
This data supports the mechanism of action of OZ277 as pro-
posed by Vennerstrom et al.10 in that carbon-centred radicals
form predominantly on the adamantane ring. Ultimately, such
adamantane radicals could alkylate parasite proteins, releasing
the remaining unlabelled cleavage product for partitioning
back into the supernatant. The fate of such products is unknown
and will be further examined in subsequent experiments designed
to assess the partitioning behaviour in a more comprehensive
manner. Further studies to explore these processes will utilize
specific analytical methods in order to characterize the nature of
the species present within the erythrocyte and the supernatant.
Similar to DHA and chloroquine,16,26 the maximum uptake of
OZ277 into infected RBCs was reached faster with mature para-
sites (30 min) than with young ring stages (2 h) (Table 1).
This result corresponds to our pharmacodynamic observations
where after a 1 h compound exposure, OZ277 and artemether
were more effective against more mature parasite stages
(Figure 2). However, after having reached the maximum uptake,
it can only be speculated as to why a steady-state phase was not
observed with [14C]OZ277[L] and [14C]OZ277[R] (Figure 3).
The relatively fast decrease in the R/P value observed with
both radioactive OZ277 variants might be an indication of
how rapidly the ring forms lose their viability, which in this
specific experiment would be after the 2 h time-point. This obser-
vation is clearly different from the results reported for
[3H]DHA,16 where using a comparable drug concentration, a
stable R/P equilibrium could be observed for 20 h.
In summary, the present study describes a significant accu-
mulation of radiolabelled OZ277, a novel peroxide-based com-
pound, in P. falciparum-infected RBCs. Similar stage-specific
profiles were found for OZ277, artemether and chloroquine.
The latter drugs are known to prevent sequestration in malaria
patients significantly by attenuating the growth of young, asexual
parasite forms.14 Since in onset and recrudescence experiments
using the P. berghei murine model, OZ277 has been shown to
clear parasitaemia rapidly to below quantifiable limits,10 the
hopes are high that OZ277 will also show similar in vivo phar-
macodynamics in malaria patients. Studies of this nature provide
further understanding of the relationship between drug concen-
tration and antimalarial effect which may ultimately help to
optimize the assessment of antimalarial efficacy and the design
of treatment regimens for malaria. Further research into the
mechanisms responsible for uptake of OZ277 (and other antimal-
arials) into infected erythrocytes will be valuable in further defin-
ing its pharmacodynamic activity.
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